D
Darrin M. Beaupre
Researcher at Amgen
Publications - 49
Citations - 4239
Darrin M. Beaupre is an academic researcher from Amgen. The author has contributed to research in topics: Ibrutinib & Mantle cell lymphoma. The author has an hindex of 21, co-authored 45 publications receiving 3579 citations. Previous affiliations of Darrin M. Beaupre include University of Texas MD Anderson Cancer Center & Yale University.
Papers
More filters
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Journal ArticleDOI
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson,Ryan M. Young,Roland Schmitz,Yandan Yang,Stefania Pittaluga,George E. Wright,Chih Jian Lih,P. Mickey Williams,Arthur L. Shaffer,John F. Gerecitano,John F. Gerecitano,Sven de Vos,Andre Goy,Vaishalee P. Kenkre,Paul M. Barr,Kristie A. Blum,Andrei R. Shustov,Ranjana H. Advani,Nathan Fowler,Julie M. Vose,Rebecca Elstrom,Thomas M. Habermann,Jacqueline C. Barrientos,Jesse McGreivy,Maria Fardis,Betty Y. Chang,Fong Clow,Brian Munneke,Davina Moussa,Darrin M. Beaupre,Louis M. Staudt +30 more
TL;DR: The selective development of ibrutinib for the treatment of ABC DLBCL is supported, with the highest number of responses occurred in ABC tumors that lacked BCR mutations, suggesting that oncogenic BCR signaling in ABC does not require B CR mutations and might be initiated by non-genetic mechanisms.
Journal ArticleDOI
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Michael L. Wang,Kristie A. Blum,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Liang Zhang,Linda Baher,Mei Cheng,Dana Lee,Darrin M. Beaupre,Simon Rule +23 more
TL;DR: With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL and is approved for patients with mantle cell lymphoma who have received one prior therapy.
Journal ArticleDOI
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Ariela Noy,Ariela Noy,Sven de Vos,Catherine Thieblemont,Peter Martin,Christopher R. Flowers,Franck Morschhauser,Graham P. Collins,Shuo Ma,Morton Coleman,Shachar Peles,Stephen C. Smith,Stephen C. Smith,Jacqueline C. Barrientos,Alina Smith,Brian Munneke,Isaiah Dimery,Darrin M. Beaupre,Robert T. Chen +18 more
TL;DR: Single-agent ibrutinib induced durable responses with a favorable benefit-risk profile in patients with previously treated MZL, confirming the role of BCR signaling in this malignancy.
Journal ArticleDOI
RAS and Leukemia: From Basic Mechanisms to Gene-Directed Therapy
TL;DR: An increasing body of data suggests that disruption of Ras signaling pathways, either directly through mutations or indirectly through other genetic aberrations, is important in the pathogenesis of a wide variety of cancers.